SELLAS Life Sciences Group, Inc. — Cyborg Score 7/10
Strong
Biopharmaceutical - Oncology (Clinical Stage)
Strategic Profile
SELLAS is advancing GPS in a Phase 3 REGAL trial evaluating it as a potential maintenance therapy in patients with acute myeloid leukemia (AML) after second complete remission, with 72 events reported as of late December 2025 (80 required for final analysis). The company has a strategic collaboration with Merck & Co., Inc. to evaluate GPS in combination with PD-1 blocker pembrolizumab in a Phase 1/2 clinical trial. SLS009 is progressing toward a U.S. enrollment launch in Q1 2026 in newly diagnosed high-risk AML, with European expansion planned for Q2 2026.
Cyborg Score Rationale
The Phase 3 REGAL trial has successfully passed interim efficacy and safety analyses with Independent Data Monitoring Committee recommending continuation. Phase 2 SLS009 data showed a 46% overall response rate in relapsed/refractory AML patients. Near-term catalysts include Phase 3 final readout and expanding clinical programs, though biotech execution risk remains.
Top Insights
Phase 3 REGAL trial imminent for final overall survival analysis, requiring only 8 more events from 72 reported as of late December 2025.
Improved liquidity position with $44.3M cash as of Q3 2025 plus approximately $83.7M in gross proceeds from warrant exercises completed or announced.
Expanding SLS009 into Europe through IMPACT-AML collaboration with U.S. and European trial launches planned for Q1-Q2 2026.
Stock has shown significant momentum with 342.98% gain over the past year, reflecting market enthusiasm for pipeline progress.
Named Competitors
AML Immunotherapies — WT1 and checkpoint inhibitor combinations for AML
CDK9 Inhibitors — Selective CDK9 inhibitors for hematologic malignancies
AML Maintenance Therapies — Venetoclax, azacitidine and combination regimens for AML
Recent Developments
(January 2026) Warrant exercise announcement generating approximately $31 million in gross proceeds with new investor warrants issued
(December 2025) Phase 3 REGAL trial update showing 72 events toward 80-event threshold for final efficacy analysis
(November 2025) Q3 2025 financial results reported with positive Phase 2 SLS009 data accepted for ASH 2025 presentation
(October 2025) R&D Day highlighting GPS and SLS009 programs; IMPACT-AML collaboration announced for SLS009 expansion
Open the full interactive SELLAS Life Sciences Group, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.